Transthyretin Stabilizer Therapy in Patients With Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Transthyretin Stabilizer Therapy in Patients With Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis

Published:2024-08-07 Issue: Volume: Page:
ISSN:1075-2765
Container-title:American Journal of Therapeutics
language:en
Short-container-title:

Author:

Faria Hilária Saugo¹^ORCID,Peixoto Bruna Pozzebon²,Sampaio Sobral Milene Vitória³,Alves Ribeiro Vitor Expedito⁴,Patricia de Souza Esther⁵,Guimarães Belchior Ana Carulina⁶

Affiliation:

1. Department of Medicine, Federal University of Santa Maria, Santa Maria (RS), Brazil

2. Department of Medicine, University of Iguaçu, Nova Iguaçu (RJ), Brazil

3. Department of Medicine, University of West São Paulo, Presidente Prudente (SP), Brazil

4. Department of Medicine, Federal University of Piauí, Teresina (PI), Brazil

5. Department of Medicine, Federal University of Grande Dourados, Dourados (MG), Brazil

6. Department of Medicine, State University of Mato Grosso do Sul, State Hospital of Mato Grosso do Sul (MS), Brazil

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference23 articles.

1. Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges;Tschöpe;J Clin Med.,2022

2. Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis;Wang;EClinicalMedicine,2023

3. Efficacy of tafamidis in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis;Sukaina;Ann Med Surg.,2024

4. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration;Liberati;BMJ,2009

5. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy;Gillmore;N Engl J Med,2024